About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
July 2005
Features
Systematic Literature Review of the Economics of Intravenous Patient-Controlled Analgesia
Most published studies of IV PCA do not include the full range of costs associated with this therapy. The author reviews some of the important cost drivers.
Alex Macario, MD, MBA
Short-Term and Long-Term Effects of Bisoprolol on Chronic Heart Failure Related to Rheumatic Heart Disease and Atrial Fibrillation
Bisoprolol appears to have the potential to improve New York Heart Association class and exercise tolerance in patients with heart failure.
Maoqin Shu, MD, Ruixia Xi, PhD, Ping Zhang, MD, Guoxiang He, PhD, Zhiyuan Song, MD, Luxiang Chi, MD, and Guoqiang Zhuang, PhD
Meeting Highlights
41st Annual Meeting of the American Society of Clinical Oncology
The authors discuss recent findings on anastrozole for the treatment of localized breast cancer, trastuzumab for HER2-positive metastatic breast cancer, zolendronic acid and bone density in women with breast cancer, gemcitabine for non–small cell lung cancer, oblimersen sodium for advanced malignant melanoma, bevacizumab for recurrent ovarian cancer, standard therapy plus oxaliplatin for colorectal cancer, lenalidomide for myelodysplastic syndromes, and raloxifene for endometrial cancer.
Lawrence M. Prescott, PhD, and Sharon L. Prescott
Meeting Highlights
158th Annual Meeting of the American Psychiatric Association
Mr. Alexander summarizes presentations on the relationship between paroxetine (Paxil®) and suicidal ideation, escitalopram (Lexapro®) for depression and comorbid anxiety, and a specialized form of methylphenidate HCl (OROS® MPH/Concerta®) for attention-deficit/hyperactivity disorder.
Walter Alexander, MS
Pharmaceutical-Approval Update
Dr. Goldenberg reviews exenatide injection (Byetta™) for diabetes, pregabalin (Lyrica™) for partial-onset seizures in adults with epilepsy, and tigecycline (Tygacil™) for skin and intra-abdominal infections.
Marvin M. Goldenberg, PhD, RPh, MS
Departments
Editorial
Technology Assessment
David B. Nash, MD, MBA, describes the work performed at the University HealthSystem Consortium and the National Association of Public Hospitals in analyzing new biotechnology products.
David B. Nash, MD, MBA
Medication Errors
Benzocaine Topical Sprays and Methemoglobinemia
Matthew Grissinger, RPh, FASCP, discusses the incidence of life-threatening methemoglobinemia and its link with the use of topical anesthetic sprays containing benzocaine.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
FDA Reform Legislation to Move Forward Soon: Bills Emphasize Better FDA Evaluation and Surveillance
Stephen Barlas comments on pressure from Congress to improve the FDA’s post-marketing surveillance of drugs for life-threatening illnesses.
Stephen Barlas
New Drugs/Drug News/New Medical Devices
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
Eszopiclone (Lunesta™): A New Non-benzodiazepine Sedative–Hypnotic
Drs. Benjamin Chavez and Jose Rey review the benefits of eszopiclone (Lunesta™) for the treatment of insomnia.
Benjamin Chavez, PharmD, and Jose A. Rey, PharmD






